Wednesday, July 8, 2026

pharma · Breast Cancer · Lumbosacral Radicular Pain · SMNR

Semnur Pharmaceuticals

Semnur Pharmaceuticals clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Palo Alto, USA HQ
2013 Founded
9 Employees
Public company Type
SMNR · NYSE Ticker
Company details
Status
Public
HQ
Palo Alto, USA
Founded
2013
Employees
9
Programs
2
Drugs
2
Patents
8
Intelligence · Clinical Programs

Semnur Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Semnur Pharmaceuticals.

Semnur Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Ixabepilone + Capecitabine

    Semnur Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial
  2. SP-102

    Semnur Pharmaceuticals

    Lumbosacral Radicular Pain

    phase 3 small molecule active

    3 trials

Frequently asked questions

How many clinical projects does Semnur Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.